This story originally ran on July 14.

By Adam Bonislawski

Proteome Sciences announced this week that it has developed two multiplex protein biomarker assays for Alzheimer's disease in collaboration with scientists at the Institute of Psychiatry, King's College, London, that it plans to commercialize by the fall.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.